<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158547</url>
  </required_header>
  <id_info>
    <org_study_id>CLR3001</org_study_id>
    <nct_id>NCT01158547</nct_id>
  </id_info>
  <brief_title>Efficacy Study of CLR3001 in Depression</brief_title>
  <official_title>A Pilot Placebo Controlled, Double-Blind, Randomized Parallel Group Study to Evaluate the Efficacy of Treatment With CLR3001 in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clera Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clera Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the ability of CLR3001 to reverse depressive symptoms&#xD;
      relatively quickly in adult patients with major depressive disorder (MDD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CLR3001 is thought to work by helping the body's natural responses overcome depression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy using Hamilton Rating Scale for Depression</measure>
    <time_frame>Weeks 2 to 7</time_frame>
  </primary_outcome>
  <enrollment type="Actual">86</enrollment>
  <condition>Depression</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female out-subjects 18-65 years.&#xD;
&#xD;
          -  Single episode or recurrent MDD (to a maximum of 5 prior episodes).&#xD;
&#xD;
          -  No current therapy for depression as per washout instructions.&#xD;
&#xD;
          -  Able to provide written informed consent.&#xD;
&#xD;
          -  Meet criteria for MDD with current MDE through MINI questionnaire.&#xD;
&#xD;
          -  Meet criteria for MDD with current MDE, as defined by DSM-IV TR.&#xD;
&#xD;
          -  HAMD-17 score ≥ 14 at screening (visit 1) and baseline (Visit 2; Randomization).&#xD;
&#xD;
          -  Able to understand and complete questionnaires, and communicate with the investigator&#xD;
             and study coordinator.&#xD;
&#xD;
          -  Judged to be reliable to keep all appointments and procedures required by the&#xD;
             protocol.&#xD;
&#xD;
          -  Female subjects of childbearing potential (who are not at least 2 years postmenopausal&#xD;
             or surgically sterile or totally abstinent) must be using a reliable, medically&#xD;
             acceptable form of contraception and must agree to continue such use throughout the&#xD;
             duration of the study. Reliable forms of contraception include oral, implanted,&#xD;
             transdermal or injected contraceptives, intrauterine devices, and adequate double&#xD;
             barrier methods including use of spermicide. Partner's vasectomy is also an acceptable&#xD;
             contraceptive regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Investigators and immediate family members.&#xD;
&#xD;
          -  Treatment within the last 90 days with a drug that had not received regulatory&#xD;
             approval at the time of study entry.&#xD;
&#xD;
          -  Persons who had previously withdrawn from this study or previous study investigating&#xD;
             CLR3001.&#xD;
&#xD;
          -  A primary diagnosis of Panic Disorder, Social Anxiety Disorder, Obsessive-Compulsive&#xD;
             Disorder within the past year.&#xD;
&#xD;
          -  The presence of an Axis II disorder, which, in the opinion of the investigator, would&#xD;
             interfere with compliance in the study.&#xD;
&#xD;
          -  History of active substance dependence within the last half-year, excluding nicotine&#xD;
             and coffee, or active substance abuse that may interfere with the outcome of the&#xD;
             study.&#xD;
&#xD;
          -  Acute suicidal ideation or risk, ≥3 on HAMD-17 suicide item.&#xD;
&#xD;
          -  Fall in HAMD-17 score greater than 20% between Visit 1 and Visit 2.&#xD;
&#xD;
          -  Serious concomitant diseases such as cancer, serious metabolic (e.g. Insulin dependent&#xD;
             diabetes), renal, cardiac, thyroid, immunological, neurological or other significant&#xD;
             disease or laboratory abnormality (hematology, blood chemistry, ECG), or treatment for&#xD;
             medical conditions which may interact with CLR3001.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding, or men or women who plan to&#xD;
&#xD;
          -  Infirmities or living in an area limiting participation in the study or compliance&#xD;
             with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidney Kennedy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>July 6, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

